Enlivex Therapeutics
ENLV
ENLV
17 hedge funds and large institutions have $630K invested in Enlivex Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.13% less ownership
Funds ownership: 1.39% → 1.25% (-0.13%)
Holders
17
Holding in Top 10
–
Calls
$52K
Puts
–
Top Buyers
| 1 | +$121K | |
| 2 | +$75.4K | |
| 3 | +$12.8K | |
| 4 |
Renaissance Technologies
New York
|
+$8.66K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.03K |
Top Sellers
| 1 | -$104K | |
| 2 | -$82.6K | |
| 3 | -$19.5K | |
| 4 |
JPMorgan Chase & Co
New York
|
-$2.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.54K |